Eton Pharmaceuticals, Inc.
ETON- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710340
In the last 90 days, Eton Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $722.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $16.5M in total
- 5
- 13F holdersQ2 2026, +49 vs. previous quarter
- 164
- 13F valueReported value at the end of Q2 2026
- $722.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ETON, Q2 2026
No superinvestor reported holding ETON at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Eton Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 (view filing)4:06 PM ET | Aug 28 | 3 days | Maier Paul VDirector | SSale | −50.0K | $59.07 | −$2.95M | −45.6%59.7K after | Amended3 lots |
| Aug 24, 2026 (view filing)5:19 PM ET | Aug 24 | Same day | Krempa DavidChief Business Officer | SSale | −25.0K | $65.07 | −$1.63M | −40.3%37.0K after | |
| Aug 20, 2026 (view filing)6:26 PM ET | Aug 19-20 | 1 day | Brynjelsen SeanPresident & CEO | SSale | −100.0K | $60.88 | −$6.09M | −9.4%961.2K after | 4 lots |
| Jul 17, 2026 (view filing)7:12 PM ET | Jul 14 | 3 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −28.3K | $37.54 | −$1.06M | −41.4%40.0K after | Amended2 lots |
| Jul 7, 2026 (view filing)6:29 PM ET | Jul 2-7 | 5 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −126.7K | $37.64 | −$4.77M | −70.4%53.3K after | 5 lots |
| Jun 17, 2026 (view filing) | Jun 17 | Same day | Adams Jennifer McKieDirector | SSale | −50.0K | $32.48 | −$1.62M | −100.0%0 after | |
| May 29, 2026 (view filing) | May 28 | 1 day | Brynjelsen SeanPresident & CEO | SSale | −120.0K | $31.88 | −$3.83M | −12.6%833.7K after | 2 lots |
| May 27, 2026 (view filing) | May 22-27 | 5 days | Krempa DavidChief Business Officer | SSale | −100.0K | $32.30 | −$3.23M | −79.8%25.2K after | 5 lots |
| Aug 20, 2025 (view filing) | Aug 19-20 | 1 day | Gruber James R.Chief Financial Officer | SSale | −41.7K | $16.15 | −$673.7K | −16.9%204.8K after | 2 lots |
| Jun 16, 2025 (view filing) | Jun 12-16 | 4 days | Krempa DavidChief Business Officer | SSale | −34.0K | $14.83 | −$504.3K | −5.3%612.6K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Eton Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 2,860,000 | $103.5M | 9.38% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 2,171,938 | $78.6M | 3.90% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,895,833 | $68.6M | 0.00% | +178,547+10.4% | Added |
| Nantahala Capital Management, LLC | 1,175,951 | $42.6M | 2.57% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 976,570 | $35.4M | 0.00% | −17,519−1.8% | Reduced |
| Morgan Stanley | 767,972 | $27.8M | 0.00% | +290,015+60.7% | Added |
| State Street Corp | 701,786 | $25.4M | 0.00% | +171,571+32.4% | Added |
| Geode Capital Management, LLC | 652,303 | $23.6M | 0.00% | +74,637+12.9% | Added |
| Oberweis Asset Management Inc | 501,600 | $18.2M | 0.38% | +62,300+14.2% | Added |
| National Philanthropic Trust | 492,112 | $17.8M | 0.26% | 00.0% | Unchanged |